Compare Futu Holdings Ltd (FUTU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Futu Holdings Ltd trades at $110.2 (market cap $15.38B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8.3× Futu Holdings Ltd's market cap, and Futu Holdings Ltd pays a 2.37% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| FUTU | VRTX | |
|---|---|---|
Market Cap | $15.38B | $128.16B |
Volume | 1,475,116 | 806,603 |
Sector | Financials | Health |
52-Week High | $199.04 | $557.96 |
52-Week Low | $89.76 | $407.37 |
Typical Hold Time | 34 Days | 120 Days |
Enterprise Value | $15.73B | $122.29B |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings (FUTU) trades at $108.76, down 3.93% on the day amid a bearish technical signal, though it remains above key support near $107. The company reported strong Q2 2026 earnings with a beat on EPS of $3.33 versus $2.98 expected, continuing robust revenue growth that reached $22.85 billion in 2025. However, a securities class action lawsuit deadline on August 25, 2026, adds near-term uncertainty.
The outlook is mixed: solid fundamentals with a low P/E of 10.95 and high net margin of 42.92% support upside potential, but technical weakness and legal overhangs pose risks. Analyst consensus is bullish with a 33.7% upside target, yet investors must weigh growth against litigation and market sentiment pressures.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
